BioAtla, Inc.
$5.69
▼
-3.12%
2026-04-21 05:35:00
www.bioatla.com
NCM: BCAB
Explore BioAtla, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.61 M
Current Price
$5.69
52W High / Low
$71.5 / $3.92
Stock P/E
—
Book Value
$-0.6
Dividend Yield
—
ROCE
732.7%
ROE
543.76%
Face Value
—
EPS
$-50.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
41
Beta
1.21
Debt / Equity
-0.17
Current Ratio
0.37
Quick Ratio
0.37
Forward P/E
-3.34
Price / Sales
3.69
Enterprise Value
$6.47 M
EV / EBITDA
-0.11
EV / Revenue
3.24
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 2. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 3. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 4. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 5. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 6. | Capricor Therapeutics, Inc. | $34.21 | — | $2.04 B | — | -33.78% | -46.56% | $40.37 / $4.3 | $5.33 |
| 7. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.26 M | -13.79 M | -18.65 M | -17.61 M | -16.24 M | — |
| Net Profit | -9.78 M | -15.78 M | -18.71 M | -15.33 M | -14.88 M | — |
| EPS in Rs | -5.9 | -9.52 | -11.29 | -9.25 | -8.98 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2 M | 11 M | 0 M | 0 M |
| Operating Profit | -59.3 M | -73.94 M | -129.69 M | -108.14 M |
| Net Profit | -59.61 M | -69.78 M | -123.46 M | -106.48 M |
| EPS in Rs | -35.97 | -42.11 | -74.51 | -64.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 13.83 M | 52.42 M | 119.66 M | 225.74 M |
| Total Liabilities | 50.02 M | 38.16 M | 48.99 M | 45.4 M |
| Equity | -36.19 M | 14.27 M | 70.67 M | 180.34 M |
| Current Assets | 8.01 M | 51.23 M | 116.41 M | 220.43 M |
| Current Liabilities | 21.92 M | 14.54 M | 28.34 M | 23.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -48.2 M | -71.94 M | -104.02 M | -90.42 M |
| Investing CF | — | 0 M | -0.1 M | -0.27 M |
| Financing CF | 6.28 M | 9.51 M | 0.08 M | 61.21 M |
| Free CF | -48.2 M | -71.94 M | -104.11 M | -90.69 M |
| Capex | — | — | -0.1 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 43.48% | -15.95% | — | — |
| Profit Margin % | -634.33% | — | — | — |
| Operating Margin % | -672.21% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -663.8% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-04-06 | 1:0.02 |